TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of supplemental beta 2-agonist medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Marginal bone loss (ΔMBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal soft tissue recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Neuropsychological measures predicting treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant stenotic coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial infarction
Endpoint domain: Adverse events/effects
Primary endpoint: BMI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distress in hepatic region improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Severe infection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: treatment duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extension of time of catheterization procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: acute complications
Endpoint domain: Adverse events/effects
Primary endpoint: fluid loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to apply
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Lid and conjunctival pathologies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success rates of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent thrombosis risk
Endpoint domain: Mortality/survival
Primary endpoint: Need for analgesics after the first 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Mean resumption of normal activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Personal well-being index (PWI)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: lower leg girth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lane-keeping performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurophysiological measures of alertness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of triggered ventilator inflations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total delivered inflation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiorespiratory parameters including CO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specimen retrieval time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative day 0 VAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐t of mefloquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of mefloquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t(1/2) of mefloquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of symptomatic or asymptomatic events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of venous thromboembolic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: caloric intake from snack foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute change in hemoglobin (g/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lysholm functional Knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-esteem
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Susceptibility to plaque‐induced gingival inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 6-year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 6-year EFS rate
Endpoint domain: Mortality/survival
Primary endpoint: Intra-observer variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall better health status perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lower average cost for drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: accessed general practitioners less frequently
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite endpoint of clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: plasminogen activator inhibitor‐1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: delaying delivery > 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extending the gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EPDS scores
Endpoint domain: Adverse events/effects
Primary endpoint: Preterm birth
Endpoint domain: Mortality/survival
Primary endpoint: Spontaneous abortions or stillbirths
Endpoint domain: Mortality/survival
Primary endpoint: PLMI ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRLS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI‐1 responders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of toxicity from topical 5-fluorouracil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental cost impact per member per month (PMPM)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of new DL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree and area of DL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DIAGNOdent values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Troponin I and T release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD4+ T-cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8+ T-cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic performance of DE-CTCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median length for healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in children's intentions to engage in risky playground behaviors
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: percentage of bone area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Hamilton scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-report inventory of depressive and anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mental health components of health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: task-focused coping and avoidant coping
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: circulating levels of high sensitivity C-reactive protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: soluble intracellular adhesion molecule-1 (sICAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: homeostasis model assessment (HOMA) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary excretion of mammalian lignans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hunger and desire to eat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps muscle tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dynamic strength-endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: limitations in daily activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: degree of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sustained improvement in behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cost-effectiveness of intensive intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance with physiotherapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in melasma grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: geometric mean serum RSV plaque‐reduction neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of treatment-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Development of transaminitis
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of urelumab 0.1 mg/kg
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical control (GH <2.5 μg/L and normal IGF‐1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Tumor volume decrease ≥20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Timing of introduction of potentially allergenic foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in Q one hour after ISMO dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fecal viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incremental effectiveness in QALYs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: decrease in total blasts count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sense of wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: appetite
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Understanding of bone mineral density definition of osteoporosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modifications in pharmacologic treatment of osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confusion about reports
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: intake frequency of unprocessed/minimally processed foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intake frequency of ultra-processed foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ADOS social affect scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-effectiveness of schema therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VAS thirst score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IDWG3d
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS xerostomia score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assessment of the periodontal ligament space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2/FiO2 ratio improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bone Mineral Density (BMD) of femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bone Mineral Density (BMD) of lumbar vertebrae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Upper gastrointestinal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in taste quality of the diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mask acceptance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety level during induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of mask fears postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: embryo aneuploidy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: number of chromosomally normal embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: rates of mosaic embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: ADL decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decline in ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death or new nursing home placement
Endpoint domain: Mortality/survival
Primary endpoint: Cost to reduce one average decayed tooth
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: stability indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean TEWL value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self-assessment of pain at removal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for tape type
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Strength in external rotation (SER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-ct) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma drug concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Farnsworth‐Munsell D100 total error score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroretinogram b-wave amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual refractive cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients receiving inappropriate medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rates after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ESR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in oxidative stress levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptoms (dry eyes and mouth dryness)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pathological complete resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of erections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall length of erectile events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of erections with rigidity >60%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of atopic eczema (AE) by 36 months
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms of poor mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in scaling on the trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marked improvement in response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma HIV‐1 RNA < or = 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ionized calcium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anhedonia score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean VAS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIL mean score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow rate of saphenous vein grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of muscle swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to mite reduction methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mite allergen levels in mattress bases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mite allergen levels in carpets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescribing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating breakfast frequency
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Plasma concentration of activated FVII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Von Willebrand factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Numeric Pain Rating Scale (NPRS) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short‐Form McGill Pain Questionnaire (SFMPQ) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities of the Arm, Shoulder, and Hand questionnaire (DASH) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cure rate at 8 weeks
Endpoint domain: Mortality/survival
Primary endpoint: cure rate at 1 year follow-up
Endpoint domain: Mortality/survival
Primary endpoint: KYN concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neopterin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in spontaneous ongoing pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in brush-induced allodynia intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mechanical hyperalgesia intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventricular enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: global and regional dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hair growth improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of eye injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of CCEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing of severe erosive esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes